AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

New Compound that Stimulates Immune Cells to Eliminate Cancers

Detailed Technology Description
None
Supplementary Information
Inventor: CHE, Chiming
Priority Number: WO2004024146A1
IPC Current: A61K0031555 | A61K00317072 | A61P003500
Assignee Applicant: The University of Hong Kong
Title: METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | PROCEDES D'UTILISATION DE COMPLEXES D'OR (III) EN TANT QU'AGENTS ANTI-TUMORAUX ET ANTI-VIH
Usefulness: METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | PROCEDES D'UTILISATION DE COMPLEXES D'OR (III) EN TANT QU'AGENTS ANTI-TUMORAUX ET ANTI-VIH
Summary: (A) is useful to induce apoptosis of cancer cells and also to inhibit human immunodeficiency virus-1 reverse transcriptase (claimed).
Novelty: Use of gold (III) complex to induce apoptosis of cancer cells and to inhibit human immunodeficiency virus-1 reverse transcriptase
Industry
Biomedical
Sub Category
Medical Composition
Application No.
9205131
Others

General Information

Cytokines, such as interferon-alpha and interleukin-2, have been used to treat cancer patients with limited success. Unfortunately, these cytokines also have profound side effects that limit their use. A UC San Diego researcher has developed a novel method to treat and prevent cancer using the cytokine IL-17D which stimulates immune cells to eliminate cancers. Such an approach does not cause side effects seen with other pro-inflammatory members of the IL-17 family.

Efficacy of this new method has been shown in mouse models; initially with overexpression of IL-17D in implanted tumor lines, but more recently using exogenously applied IL-17D as would occur in clinical use. Although a full publication on this material is still pending, two abstracts may be reviewed at:

IL-17D mediated cancer rejection
Timothy O'Sullivan, Robert Saddawi-Konefka, and Jack Bui


IL-17D, natural killer cells, and macrophages collaborate to promote tumor rejection (P2097) Jack Bui, Timothy O'Sullivan, Robert Saddawi-Konefka, and Emilie Gross

Detailed description of technoogy is available under secrecy agreement.  


Tech ID/UC Case

22177/2011-202-0


Related Cases

2011-202-0

*Abstract
None
*IP Issue Date
Dec 8, 2015
*Principal Investigator

Name: Jack Bui

Department:

Country/Region
USA

For more information, please click Here
Mobile Device